Get the Stockscreener App
1.15
8.00%
-0.10
After Hours:
1.17
0.02
+1.74%
Milestone Pharmaceuticals Inc stock is traded at $1.15, with a volume of 1.50M.
It is down -8.00% in the last 24 hours and down -33.14% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
1.50M
Relative Volume:
0.59
Market Cap:
$135.32M
Revenue:
$1.55M
Net Income/Loss:
$-63.06M
P/E Ratio:
-1.4449
EPS:
-0.7959
Net Cash Flow:
$-49.45M
1W Performance:
-32.35%
1M Performance:
-33.14%
6M Performance:
-42.50%
1Y Performance:
-42.79%
1-Day Range:
$1.15
$1.25
1-Week Range:
$1.11
$1.61
52-Week Range:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.15 | 147.08M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Aug Chart Watch: Is Milestone Pharmaceuticals Incs ROIC above industry averageForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals - Markets Mojo
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan
Equities Analysts Issue Forecasts for MIST FY2028 Earnings - MarketBeat
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals - The Globe and Mail
MIST PE Ratio & Valuation, Is MIST Overvalued - Intellectia AI
Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Why Milestone Pharma Stock Is Taking A Dive Today - Sahm
Why Milestone Pharma stock is taking a dive today - MSN
How does Milestone Pharmaceuticals Inc compare to its peersIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highl - GuruFocus
S P Trends: Does Milestone Pharmaceuticals Inc have consistent dividend growth2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Buyback Watch: What is the long term forecast for Milestone Pharmaceuticals Inc stock2026 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations - StocksToTrade
Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target - TipRanks
Missing Data on MIST: Insights and Analysis - timothysykes.com
Milestone Pharmaceuticals Reports 2025 Financial Results and Launch of FDA-Approved CARDAMYST Nasal Spray for PSVT - Minichart
Milestone Pharmaceuticals 2025 Annual Report: CARDAMYST™ (etripamil) Launch, Business Overview, and Key Risks - Minichart
Milestone Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Milestone Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Milestone Pharmaceuticals meets EPS forecast, stock dips - Investing.com
Milestone Advances CARDAMYST Launch After Landmark PSVT Approval and Bolsters Cash Runway - TipRanks
Milestone Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Milestone Pharmaceuticals (MIST) Reports Strong Financial and Ma - GuruFocus
Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c) - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - The Manila Times
CARDAMYST launch and 2025 results for Milestone Pharmaceuticals (Nasdaq: MIST) - Stock Titan
Milestone Pharmaceuticals 10‑K: $1.55M Revenue, ($0.75) EPS on $63.1M Net Loss - TradingView
Earnings Scheduled For March 20, 2026BitFuFu (NASDAQ:FUFU), Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga
Milestone (MIST) wins FDA nod for CARDAMYST and maps AFib-RVR Phase 3 - Stock Titan
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
Investment Review: Should I invest in Milestone Pharmaceuticals Inc before earningsQuarterly Profit Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Milestone Pharmaceuticals (MIST) Highlights Etripamil's Safety a - GuruFocus
Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - Bitget
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times
FDA-approved PSVT nasal spray shows minimal blood pressure change - Stock Titan
Boxer Capital Management LLC Invests $1.33 Million in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality - Seeking Alpha
Milestone Pharmaceuticals Sets March 20 Call for 2025 Results and Business Update - TipRanks
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - Bitget
Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan
Swing Trade: What is the long term forecast for Milestone Pharmaceuticals Inc stockWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Wells Fargo Initiates Coverage of Milestone Pharmaceuticals (MIST) with Overweight Recommendation - MSN
Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):